Loading
SRD5A1 (3-oxo-5-alpha-steroid 4-dehydrogenase 1) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer.
Catalyses the irreversible stereospecific reduction of the delta 4,5 bond (double bond between carbons 4 and 5) of various 3-oxo steroids (3-keto steroids) producing their 5alpha dihydro-3-oxo forms. Converts testosterone into 5-alpha-dihydrotestosterone (DHT), a more potent androgen as it is the preferred ligand for androgen receptor (AR) transactivation, making this reaction a key step in male sexual differentiation during development. Besides testosterone, it can also act on other steroids, including progesterone, androstenedione, and corticoids, producing metabolites with diverse roles.
Open Targets scores its association with cancer at 0.61 (direct and indirect evidence; datatypes literature 0.82, genetic association 0.03, clinical 0.96).
In plain words · SRD5A1 (3-oxo-5-alpha-steroid 4-dehydrogenase 1) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer.
SRD5A1 (3-oxo-5-alpha-steroid 4-dehydrogenase 1) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer.
Catalyses the irreversible stereospecific reduction of the delta 4,5 bond (double bond between carbons 4 and 5) of various 3-oxo steroids (3-keto steroids) producing their 5alpha dihydro-3-oxo forms.
No product in this corpus aims at SRD5A1 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA SRD5A1: RNA tissue enhanced (liver 27 nTPM); high antibody staining in 7 normal tissues; highest cancer staining prostate cancer (4 of 12 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Prostate cancer); Open Targets associates it with 3 specific cancer types at or above 0.5 (benign prostatic hyperplasia, prostate cancer, prostate carcinoma); the corpus evidence decides and the Open Targets list is quoted for comparison. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas SRD5A1 tissue; Open Targets ENSG00000145545 associations
First described 1990. Earliest sequence paper UniProt cites for the protein: Andersson et al, Proc. Natl. Acad. Sci. U.S.A, 1990, "Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha-reductases". Source.
Sources: HGNC HGNC:11284 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P18405 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000145545 (association with cancer (MONDO_0004992) 0.61; per-cancer scores at or above 0.5: prostate cancer 0.60 (GraphQL API, CC0))
Catalyses the irreversible stereospecific reduction of the delta 4,5 bond (double bond between carbons 4 and 5) of various 3-oxo steroids (3-keto steroids) producing their 5alpha dihydro-3-oxo forms. Converts testosterone into 5-alpha-dihydrotestosterone (DHT), a more potent androgen as it is the preferred ligand for androgen receptor (AR) transactivation, making this reaction a key step in male sexual differentiation during development. Besides testosterone, it can also act on other steroids, including progesterone, androstenedione, and corticoids, producing metabolites with diverse roles. Hence, it plays a central role in sexual differentiation and androgen physiology. Location: Microsome membrane; Endoplasmic reticulum membrane (UniProt). Locus 5p15.31 (HGNC).
RNA: tissue enhanced (liver 27 nTPM), detected in many normal tissues.
Medium: Cerebellum, Colon, Duodenum, Gallbladder, Hippocampus, Liver, Lung, Nasopharynx.
Medium only: breast cancer, cervical cancer, glioma, head and neck cancer.
HPA SRD5A1 tissue · HPA SRD5A1 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"SRD5A1" OR ABSTRACT:"SRD5A1" OR TITLE:"steroid 5 alpha-reductase 1" OR ABSTRACT:"steroid 5 alpha-reductase 1" OR TITLE:"3-oxo-5-alpha-steroid 4-dehydrogenase 1" OR ABSTRACT:"3-oxo-5-alpha-steroid 4-dehydrogenase 1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SRD5A1, not a curated reading list.